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ABSTRACT
Objectives To examine whether second-hand smoke
(SHS) exposure measured by serum cotinine is
associated with increased coronary heart disease (CHD)
and stroke risk among contemporary older British adults.
Design Prospective population-based study with self-
reported medical history and health behaviours. Fasting
blood samples were analysed for serum cotinine and
cardiovascular disease (CVD) risk markers.
Setting Primary care centres in 25 British towns in
1998e2001.
Patients 8512 60e79-year-old men and women
selected from primary care registers.
Main outcome measures Fatal and non-fatal
myocardial infarction (MI; n¼445) and stroke (n¼386)
during median 7.8-year follow-up.
Main exposure Observational study of serum cotinine
assayed from fasting blood sample using liquid
chromatography tandem mass spectrometry method,
and self-reported smoking history.
Results Among 5374 non-smokers without pre-existing
CVD, geometric mean cotinine was 0.15 ng/ml (IQR
0.05e0.30). Compared with non-smokers with cotinine
#0.05 ng/ml, higher cotinine levels (0.06e0.19,
0.2e0.7 and 0.71e15.0 ng/ml) showed little association
with MI; adjusted HRs were 0.92 (95% CI 0.63 to 1.35),
1.07 (0.73 to 1.55) and 1.09 (0.69 to 1.72), p(trend)¼
0.69. Equivalent HRs for stroke were 0.82 (0.55 to 1.23),
0.74 (0.48 to 1.13) and 0.69 (0.41 to 1.17), p(trend)¼
0.065. The adjustment for sociodemographic,
behavioural and CVD risk factors had little effect on the
results. The HR of MI for smokers (1e9 cigarettes/day)
compared with non-smokers with cotinine #0.05 ng/ml
was 2.14 (1.39 to 3.52) and 1.03 (0.52 to 2.04) for
stroke.
Conclusions In contemporary older men and women,
SHS exposure (predominantly at low levels) was not
related to CHD or stroke risks, but we cannot rule out the
possibility of modest effects at higher exposure levels.
INTRODUCTION
Second-hand tobacco smoke (SHS) exposure
appears to increase the risks of coronary heart
disease (CHD). Previous prospective studies of self-
reported SHS exposure estimated the risk of CHD
to be increased by 1.2- to 1.3-fold, independently of
established CHD risk factors.
1 2 These studies were
subsequently supported by the results of a large
international caseecontrol study of CHD risk
factors
3 and by ecological studies of CHD mortality
and morbidity rates in communities enacting bans
on smoking in public places, which tended to ﬁnd





studies report increased risks of ischaemic stroke
associated with self-reported SHS exposure, though
others did not identify signiﬁcantly increased risks
for new-onset stroke
14 in non-smokers, or cerebro-
vascular mortality
15 in never-smokers.
Self-reported SHS exposure is an imprecise
exposure measure. A recent prospective study used
serum cotinine, a stable metabolite of nicotine, as
a marker of SHS exposure and found that high
levels of SHS exposure (serum cotinine levels
>0.7 ng/ml) may increase CHD risk by 1.4- to 1.5-
fold.
16 Moreover, a recent cross-sectional study
based on data from the Third National Health and
Nutrition Examination Survey (NHANES III)
showed that low-level SHS exposure (cotinine
levels as low as 0.2 ng/ml) may inﬂuence inﬂam-
matory markers, though the association with CHD
events was not studied.
17 These studies suggest
that the impact of SHS may have been under-
estimated in earlier studies and that large prospec-
tive studies using cotinine to examine the impact of
SHS exposure on CHD and stroke events, particu-
larly at lower cotinine levels and among popula-
tions with high CHD and stroke risk, are needed.
We have therefore examined the associations
between cotinine level, CHD and stroke in parallel
studies of older British men and women who were
initially studied in 1998e2001, when SHS expo-





In 1998e2000, a total of 4252 men from a single
general practice (primary care centre) in each of
24 British towns who were already participating
in a prospective study of cardiovascular disease
(CVD) attended for follow-up measurements at age
60e79 years (77% response rate).
19 In 1999e2001,
a parallel study of 4286 women of the same age
and in the same practices was established, with the
addition of one study town (Bristol) and the
omission of two others (Dewsbury and Maidstone)
(60% response rate).
20 Almost identical protocols
for data collection were used. Ethical approval was
provided by all relevant local research ethics
committees. All participants provided written
informed consent to the investigations, which were
carried out in accordance with the Declaration of
Helsinki. Participants completed questionnaires
including detailed questions about current and pre-
vious smoking history (cigarettes, pipes and cigars),
other health behaviours, occupation and medica-
tion use. Participants reported whether their spouse
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Smoking and cardiovascular diseaseor partner smoked and if they currently lived alone or with
their partner. Those cohabiting and reporting that the partner
smoked were coded as exposed to SHS at home, while those
cohabiting and reporting that the partner did not currently
smoke, and those living alone were coded as not exposed to
SHS at home. Nurses made physical measurements and
collected fasting venous blood samples (see online supple-
mentary data).
Laboratory assays
Serum samples were assayed for cotinine in 2007e8a tA B S
Laboratories Ltd. For non-smokers a liquid chromatography
tandem mass spectrometry assay with a lower limit of detection
of 0.02 ng/ml and with a limit of quantiﬁcation of 0.1 ng/ml
was used.
21 Cotinine values at the limit of quantiﬁcation
(0.1 ng/ml) were assigned a value of 0.05 ng/ml, as in other
studies,
22 and statistical sensitivity analyses (using values of
0.025 and 0.075 ng/ml instead) assessed the validity of this
assumption. Further details of the assay can be obtained from
abslabs@biopark.org.uk. Assays for blood lipids and inﬂamma-
tory markers are described in the online supplementary data.
Classiﬁcation of smokers and non-smokers
Non-smokers reported no current cigarette, cigar or pipe
smoking or any smoking in the past 5 years and had serum
cotinine levels #15 ng/ml, consistent with other literature.
22
Among 7161 self-reported non-smokers, 7085 (99%) had cotinine
levels #15 ng/ml, the remaining 76 (1%) participants with
cotinine >15 ng/ml were recoded as smokers of 1e9 cigarettes/
day, as their cotinine levels were similar to those of the other
(n¼230) light smokers. No participants reported taking nicotine
replacement therapy (British National Formulary code 4.10).
23
CHD and stroke outcome
The outcome measures used were ﬁrst fatal or non-fatal event of
(a) myocardial infarction (MI) and (b) stroke occurring after the
1998e2000 survey (men) and 1999e2001 survey (women) and
up to June 2008 (men) and September 2007 (women). Fatal cases
were ascertained through the National Health Services Central
Registers (death certiﬁcates with ICD-9 (International Classiﬁ-
cation of Diseases) codes 410e414 for MI and 430e438 for
stroke and ICD 10 codes I21eI23, I252 for MI and I60, I61, I62,
I629, I63-I66, I67, I672, I678, I679, I69, G450e453, G46 for
stroke). Non-fatal events were recorded from 2-yearly reviews of
patient primary care notes (including details of patient
encounters with primary care and all correspondence and diag-
noses from secondary care). MI was reported as heart attack or
coronary thrombosis, diagnosed in accordance with WHO
criteria; stroke was reported as cerebrovascular accident, cerebral
thrombosis, haemorrhage or embolism.
Statistical methods
Serum cotinine was highly positively skewed and therefore
analysed as a categorical variable. The threshold for the highest
exposure group (>0.7 ng/ml) was chosen because cotinine
>0.7 ng/ml has been reported to be associated with increased
CHD risks
16 and because of the generally low cotinine levels in
non-smokers in our study, there were too few participants to
further subdivide those above this level. The lowest group had
undetectable exposure (#0.05 ng/ml) and participants with
intermediate exposure were split into two equal-sized groups.
Analyses were also completed with cotinine as a continuous
variable that was log transformed (to base 2) to approximate
normality.
Means, medians or proportions of behavioural and demo-
graphic factors selected a priori were calculated for groups of
passive smokers (deﬁned by cotinine level) and active smokers
(deﬁned by cigarettes/day). Linear trends across cotinine cate-
gories were tested using linear regression analyses with log2
cotinine as a predictor, to represent the effect of a doubling of
cotinine concentration, adjusted for age, gender and region of
residence. Skewed variables were natural log-transformed and
adjusted for time of measurement if they showed signiﬁcant
diurnalvariation.Bloodpressure(BP),bodymassindex(BMI)and
forced expiratory volume in 1 s (FEV1) were also adjusted for
intraobserver variation. No diurnal or seasonal (OctobereMarch
vs AprileSeptember) variation in cotinine levels was seen.
Cox proportional hazards regression models were used to
estimate associations between serum cotinine and risk of CHD
or stroke in non-smokers with complete data on covariates.
Survival times were censored at date of MI or stroke, death from
any cause, or end of follow-up period, whichever occurred ﬁrst.
Date of entry into the study was used as the time origin. The
proportional hazards assumption was examined using time-
varying covariates, calculating interactions of predictor variables
and a function of survival time and including them in the
models. Examination of time-varying covariates did not indicate
violation of the proportionality assumption in the non-smoker
sample. The HRs for categories of cotinine exposure compared
with cotinine #0.05 were estimated and the overall association
in non-smokers was tested with the continuous association
between log2 cotinine and CHD or stroke risk, adjusted for
gender, age (continuous variable) and region of residence. Models
were adjusted for covariates associated with both CHD risk and
SHS, ﬁrst established biological risk factors and inﬂammatory
markers as continuous variables: systolic and diastolic BP, total
and high-density lipoprotein cholesterol, BMI, FEV1, natural log
triglycerides and white cell count, C-reactive protein (CRP) and
interleukin 6 (IL-6). Models were then further adjusted for pre-
existing diabetes (yes/no) and behavioural risk factors as cate-
gorical variables: physical activity (inactive (<3 h moderate or
vigorous activity/week) or active), alcohol intake (none/occa-
sional, light, heavy), social class (I and II, III non-manual, III
manual, IV and V manual and armed forces). Interactions with
gender and age were tested using likelihood ratio (LR) tests. In
a sensitivity analysis, regression models excluded past smokers
from the non-smoker group. All hypothesis tests were two sided
and signiﬁcance levels are reported.
RESULTS
Among 8512 participants (4267 women, 4245 men), 7375 had
questionnaire data on cigarette smoking and cotinine data.
Participants with a history (self-report or medical record) of MI
or stroke (n¼1168), current smokers of $10 cigarettes/day
(n¼276) and recent ex-smokers (within 5 years) (n¼251) were
excluded from analyses. The analysis sample included 5374 non-
smokers (of whom 2783, 52% were never-smokers) and, as
a comparison group, 306 smokers of 1e9 cigarettes/day. In the
analysis sample of 5680 participants, there were 217 new MI
cases (192 in non-smokers) and 176 new stroke cases (165 in
non-smokers) in mean follow-up times of 8.3 years (men) and
7.0 years (women). Geometric mean cotinine level was
104.57 ng/ml (IQR 66e227) in active smokers (1e9 cigarettes/
day) and 0.15 ng/ml (IQR 0.05e0.30) in non-smokers (p no
difference <0.001). Of the 5374 non-smokers, 2256 (42%) had
undetectable cotinine levels (#0.05 ng/ml). Table 1 shows the
characteristics of SHS-exposed non-smokers and of active
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Smoking and cardiovascular diseasesmokers, both compared with the baseline group of non-smokers
with undetectable SHS exposure (cotinine #0.05 ng/ml). Active
smokers tended to be resident in the north of the UK, from
manual social class and physically inactive compared with non-
smokers with undetectable SHS exposure. Non-smokers with
higher serum cotinine levels, indicating greater SHS exposure,
were also resident in the north of the UK, from manual social
class, physically inactive and younger, male, ex-smokers rather
than never-smokers, and less likely to be non-drinkers or occa-
sional alcohol drinkers compared with non-smokers with
undetectable SHS exposure. Among non-smokers, cotinine level
was positively and signiﬁcantly associated with higher CRP, IL-6
and BMI and with lower FEV1. Blood pressure, lipids and pre-
existing diabetes showed no association with cotinine. Active
smokers, had lower BMI, systolic BP, diastolic BP and FEV1 but
higher triglycerides, CRP, IL-6 and white cell count than non-
smokers with undetectable SHS exposure.
In Cox proportional hazard models examining the association
between cotinine level and CHD risk among non-smokers
and adjusted for age, gender and region of residence (table 2,
model 1), a doubling of cotinine level was not strongly associ-
ated with CHD risk: HR 1.02 (95% CI 0.95 to 1.11), p¼0.56.
Increasing cotinine categories showed no appreciable association
with CHD risk when compared with participants with cotinine
#0.05 ng/ml. Further adjustments for established cardiovascular
risk factors and inﬂammatory markers (model 2) and pre-
existing diabetes, social class and behavioural risk factors (model
3) did not materially alter the results. LR tests showed no
evidence for interactions of cotinine on risk of MI by gender
(p¼0.94) or age (p¼0.65). Exclusion of ex-smokers did not
materially affect the results. In contrast, active smokers, when
compared with the same reference group (non-smokers with
cotinine #0.05 ng/ml) had a HR for MI of 2.53 (95% CI 1.61 to
3.99), reducing slightly to 2.14 (95% CI 1.39 to 3.52) after
adjustment for established risk factors (equivalent to model 3 in
table 2).
In Cox proportional hazard models examining the association
between cotinine level and stroke risk among non-smokers
and adjusted for age, gender and region of residence (table 3,
model 1), increasing cotinine levels showed a weak inverse
association with stroke risk compared with participants with
cotinine #0.05 ng/ml. A doubling of cotinine level was associ-
ated with a decrease in stroke risk of 0.91 (95% CI 0.83 to 1.01),
p¼0.07. Further adjustments for established cardiovascular risk
factors, social class and inﬂammatory markers (models 2 and 3)
did not materially alter the results. LR tests showed no evidence
for interactions of cotinine on risk of stroke by gender (p¼0.92)
or age (p¼0.83). Exclusion of ex-smokers did not materially
affect the results. Active smokers, when compared with the
same reference group (non-smokers with cotinine #0.05 ng/ml)
had a HR for stroke of 1.13 (95% CI 0.60 to 2.13), reducing to
1.03 (95% CI 0.52 to 2.04) after adjustment (equivalent to model
3 in table 3).
Analyses presented were not inﬂuenced either by the cotinine
threshold used to deﬁne active smoking (use of a more conser-
vative cotinine threshold (9.5 ng/ml)
24 did not materially affect
results), or by the duration of follow-up period (HRs did not
differ between early and late follow-up periods).
Among participants with data on self-reported exposure to
SHS in the home (n¼4818), 485 (10%) lived with a spouse/
Table 1 Association between serum cotinine in non-smokers ($5 years since quitting) or active smokers and cardiovascular disease risk factors in
men and women (mean (SD) or %(n))*
Risk factors
Non-smokers (serum cotinine ng/ml) Smokers p(trend)y p(difference)y
N
£0.05 0.06e0.19 0.20e0.70 0.71e15 1e9 Cigarettes/day
(n[306) In non-smokers
Cotinine £0.05
vs smokers (n[2256) (n[1248) (n[1184) (n[686)
Cotinine (ng/ml)z 5680 0.05 0.14 0.34 1.69 104.57 ee
Age (years) 5680 69.3 (5.5) 68.4 (5.5) 68.2 (5.5) 68.1 (5.4) 69.1 (5.3) <0.001 0.526
Men % (n) 5680 38.3 (865) 45.1 (563) 51.6 (611) 55.5 (381) 39.4 (121) <0.001 0.516
Southern region of residence, % 5680 43.4 (981) 32.2 (402) 27.4 (324) 20.7 (142) 30.4 (93) <0.001 0.001
Manual occupational class, % 5345 41.0 (880) 45.5 (539) 56.5 (626) 65.7 (418) 55.3 (147) <0.001 <0.001
Never/occasional alcohol use, % 5397 52.1 (1128) 48.0 (571) 41.7 (475) 40.1 (256) 54.5 (145) <0.001 0.589
>43 Alcohol units/week, % 5397 0.4 (9) 0.3(4) 1.6 (18) 4.2 (27) 0.8 (2) <0.001 0.518
Never-smokers, % 5680 56.7 (1278) 54.1 (675) 46.6 (552) 40.5 (278) e <0.001 e
Low level of physical activity, %
(<3 h moderate/vigorous /week)
5645 62.9 (1377) 59.6 (721) 61.2 (698) 62.4 (406) 74.6 (206) 0.002 <0.001
Pre-existing diabetes, % 5680 10.2 (230) 8.5 (106) 11.5 (136) 10.5 (72) 9.8 (30) 0.762 0.791
Body mass index (kg/m
2) 5647 26.9 (4.3) 27.4 (4.1) 27.8 (4.5) 27.8 (4.5) 25.8 (3.9) <0.001 <0.001
Systolic Blood Pressure (mm Hg)x 5646 149.5 (24.3) 147.7 (24.5) 147.6 (24.1) 150.3 (24.1) 146.1 (25.4) 0.690 0.018
Diastolic Blood Pressure (mm Hg)x 5646 82.3 (11.5) 82.0 (11.4) 82.7 (12.1) 84.1 (11.9) 80.8 (11.6) 0.096 0.030
Total cholesterol (mmol/l) 5648 6.5 (1.2) 6.4 (1.2) 6.3 (1.1) 6.3 (1.2) 6.4 (1.2) 0.131 0.353
HDL cholesterol (mmol/l) 5629 1.6 (0.4) 1.5 (0.4) 1.5 (0.4) 1.5 (0.4) 1.5 (0.5) 0.160 0.151
Triglyceride (mmol/l)z{ 5495 1.6 1.6 1.6 1.6 1.7 0.100 0.016
C-reactive protein (mg/l)z 5601 1.5 1.5 1.7 1.9 2.3 <0.001 <0.001
IL-6 (pg/ml)z 5640 2.2 2.2 2.3 2.5 3.1 <0.001 <0.001
White cell count (310
9/l)z{ 5418 6.6 6.7 6.7 6.7 7.8 0.062 <0.001
FEV1x** 5680 2.3 (0.5) 2.3 (0.5) 2.3 (0.5) 2.2 (0.6) 2.0 (0.6) <0.001 <0.001
*Non-smoker sample excludes (i) current cigarette, pipe or cigar smokers, (ii) ex-smokers who quit <5 years ago, (iii) pre-existing myocardial infarction or stroke. Means are adjusted for age,
gender and region;
yp(trend) from linear regression models of ln(cotinine) in non-smokers, p(difference) from linear regression models contrasting cotinine<0.05 with 1e9/day smokers. Models adjusted for age,
gender and region;
zgeometric mean;
xadjusted for interobserver variation;
{Adjusted for time of day;
**adjusted for height squared and age.
FEV1, forced expiratory volume in 1 s; HDL, high-density lipoprotein; IL, interleukin.
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Smoking and cardiovascular diseasepartner who smoked and 4333 (90%) did not live with a partner
who smoked; geometric mean cotinine in these groups were
respectively 0.13 ng/ml (IQR 0.05e0.25) and 0.70 ng/ml (IQR
0.22e2.4). Non-smoking participants who lived with a smoker
had a HR for CHD of 1.33 (95% CI 0.82 to 2.15) and a HR for
stroke of 0.53 (95% CI 0.25 to 1.16) compared with those not
living with a smoker, adjusted for age, gender and region. Further
adjustments for established cardiovascular risk factors, social
class and inﬂammatory markers did not materially alter the
results and there was no evidence of effect modiﬁcation by
gender or age. Restricting analyses to never-smokers, in the
sample with full covariate data: 110 (7%) lived with a smoker
and 1457 (93%) did not, geometric mean cotinine levels were
respectively 0.12 ng/ml (IQR 0.05e0.21) and 0.74 ng/ml
(IQR 0.25e2.46). Never-smoking participants who lived with a
smoker compared with those who did not live with a smoker
Table 2 Hazard ratios (HRs) for risk of myocardial infarction (MI) in men and women by serum cotinine or active smoking level
Non-smokers (serum cotinine ng/ml) (n[4608)* Smokers (n[242*) All non-smokers
£0.05 0.06e0.19 0.20e0.70 0.71e15 1e9 Cigarettes/day Cotinine £15 ng/mly p(trend)y
Mean cotinine (ng/ml) 0.05 0.14 0.34 1.71 100.02 0.15
Number of participants 1943 1087 1018 560 242 4608
Number of events 77 40 47 28 25 192
Person-years 14641 8323 7902 4333 1701 35199
CHD rates/1000 5.26 4.81 5.95 6.46 14.67 5.45
HR (95% CI)
Model 1 1.00 0.92 (0.63 to 1.35) 1.09 (0.76 to 1.58) 1.11 (0.72 to 1.73) 2.53 (1.61 to 3.99) 1.02 (0.95 to 1.11) 0.562
Model 2 1.00 0.92 (0.62 to 1.35) 1.09 (0.75 to 1.58) 1.09 (0.70 to 1.71) 2.07 (1.26 to 3.40) 1.02 (0.94 to 1.10) 0.644
Model 3 1.00 0.92 (0.63 to 1.35) 1.07 (0.73 to 1.55) 1.09 (0.69 to 1.72) 2.14 (1.39 to 3.52) 1.02 (0.94 to 1.11) 0.690
Excluding former smokers (n[2321) (n[239)
Mean cotinine (ng/ml) 0.05 0.14 0.33 1.76 100.02 0.13
Number of participants 1081 572 458 210 239 2321
Number of events 34 17 16 7 25 74
Person-years 8034 4349 3521 1582 1687 17486
CHD rates/1000 4.23 4.35 4.54 4.42 14.82 4.23
HR (95% CI)
Model 1 1.00 0.90 (0.50 to 1.62) 1.03 (0.56 to 1.88) 1.01 (0.44 to 2.32) 2.52 (1.48 to 4.29) 1.01 (0.88 to 1.17) 0.858
Model 2 1.00 0.90 (0.49 to 1.60) 0.98 (0.53 to 1.81) 0.95 (0.41 2.20) 2.10 (1.17 to 3.76) 1.00 (0.87 to 1.16) 0.985
Model 3 1.00 0.91 (0.50 to 1.63) 0.99 (0.53 to 1.84) 0.94 (0.40 to 2.24) 2.17 (1.20 to 3.90) 1.00 (0.86 to 1.16) 0.975
*HRs for non-smokers from models with cotinine #0.05 as baseline. HRs for smokers from models comparing cotinine #0.05 with smokers of 1e9 cigarettes/day. Participants with pre-
existing myocardial infarction are excluded.
yFrom Cox regression models of log2(cotinine) level (representing a doubling in cotinine) and CHD in non-smokers, cotinine #15 ng/ml.
Model 1 ¼ age+gender+region; Model 2 ¼ model 1+BMI+SBP+DBP+total cholesterol+HDLc+triglycerides+FEV1+CRP+IL-6+white cell count; Model 3 ¼ model 2+pre-existing
diabetes+physical activity (inactive or active)+alcohol intake (none/occasional, light, heavy)+smoking history (never/ time since quitting)+social class (non-manual, manual and armed forces).
CHD, coronary heart disease; CRP, C-reactive protein; FEV1, forced expiratory volume in 1 s; HDLc, high-density lipoprotein cholesterol; IL, interleukin.
Table 3 Hazard ratios (HRs) for risk of stroke in men and women by serum cotinine or active smoking level
Non-smokers (serum cotinine ng/ml) (n[4405)* Smokers (n[228) Non-smokers
£0.05 0.06e0.19 0.20e0.70 0.71e15 1e9 Cigarettes /day Cotinine £15 ng/mly p(trend)y
All participants
Mean cotinine (ng/ml) 0.05 0.14 0.34 1.70 100.01 0.15
Number of participants 1858 1031 975 541 228 4405
Number of events 80 34 32 19 11 165
Person-years 13990 7901 7593 4182 1602 33666
Stroke rates/1000 5.72 4.30 4.21 4.54 6.87 4.90
HR (95% CI)
Model 1 1.00 0.78 (0.52 to 1.17) 0.73 (0.48 to 1.10) 0.74 (0.44 to 1.23) 1.13 (0.60 to 2.13) 0.91 (0.83 to 1.01) 0.051
Model 2 1.00 0.81 (0.54 to 1.22) 0.75 (0.50 to 1.15) 0.69 (0.41 to 1.16) 1.03 (0.52 to 2.04) 0.91 (0.83 to 1.00) 0.051
Model 3 1.00 0.82 (0.55 to 1.23) 0.74 (0.48 to 1.13) 0.69 (0.41 to 1.17) 1.03 (0.52 to 2.04) 0.91 (0.82 to 1.01) 0.065
Excluding former smokers (n[2232) (n[228)
Mean cotinine (ng/ml) 0.05 0.14 0.33 1.74 100.01 0.13
Number of participants 1036 550 441 205 230 2232
Number of events 37 17 10 6 11 70
Person-years 7717 4162 3401 1550 1615 16830
Stroke rates/1000 4.79 4.08 2.94 3.87 6.81 4.16
HR (95% CI)
Model 1 1.00 0.87 (0.49 to 1.55) 0.62 (0.30 to 1.26) 0.86 (0.36 to 2.07) 1.07 (0.53 to 2.15) 0.95 (0.81 to 1.11) 0.526
Model 2 1.00 0.90 (0.50 to 1.62) 0.60 (0.29 to 1.22) 0.78 (0.32 to 1.89) 1.12 (0.50 to 2.47) 0.94 (0.80 to 1.10) 0.407
Model 3 1.00 0.91 (0.50 to 1.62) 0.61 (0.30 to 1.26) 0.81 (0.33 to 1.99) 1.21 (0.55 to 2.65) 0.94 (0.80 to 1.11) 0.476
*HRs for non-smokers from models with cotinine #0.05 as baseline. HRs for smokers from models comparing cotinine #0.05 with smokers of 1e9 cigarettes/day. Participants with pre-
existing myocardial infarction or stroke are excluded.
yFrom Cox regression models of log2(cotinine) level (representing a doubling in cotinine) and stroke in non-smokers, cotinine #15 ng/ml.
Model 1 ¼ age+gender+region; Model 2 ¼ model 1+BMI+SBP+DBP+total cholesterol+HDLc+triglycerides+FEV1+CRP+IL-6+white cell count; Model 3 ¼ model 2+pre-existing
diabetes+physical activity (inactive or active)+alcohol intake (none/occasional, light, heavy)+smoking history (never/ time since quitting)+social class (non-manual, manual and armed forces).
CHD, coronary heart disease; CRP, C-reactive protein; FEV1, forced expiratory volume in 1 s; HDLc, high-density lipoprotein cholesterol; IL, interleukin.
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Smoking and cardiovascular diseasehad an age, gender and region adjusted HR for CHD of 2.17
(95% CI 0.97 to 4.84) strengthening to 2.41 (95% CI 1.04 to 5.59)
on full adjustment, and a fully adjusted HR for stroke of
0.69 (95% CI 0.16 to 2.94). There was no evidence for effect




In this population of older men and women with low levels of
SHS exposure (indicated by low mean levels of serum cotinine
among non-smokers and also the small prevalence (just 10%) of
self-report of living with a partner who smoked) there was little
evidence for an association between SHS exposure and either MI
or stroke, irrespective of whether these were never-smokers or
ex-smokers. These ﬁndings did not vary by age or by gender.
However, there was evidence of a raised risk of MI in never-
smokers who lived with a smoker, though the conﬁdence limits
are wide and this was a post hoc analysis.
Relation to earlier studies
Previous studies and meta-analyses have shown that SHS
exposure, particularly deﬁned by partner smoking, is associated
with a 25e30% increase in risk of CHD,
1 22 5an estimate
recently supported by the INTERHEART Study.
3 Evidence from
cotinine-based studies suggests that the increase in CHD risk at
high overall SHS exposure (particularly at exposure levels asso-
ciated with cotinine concentrations >0.7 ng/ml) may exceed
these earlier estimates, and be as high as 45e50%.
16 Subse-
quently, cross-sectional studies relating cotinine levels to inter-
mediate markers such as ﬁbrinogen and white cell count have
suggested that the effects of cotinine on cardiovascular risk
might begin at SHS exposure levels associated with lower coti-
nine concentrations (<0.7 ng/ml).
17 26
Our investigation is the ﬁrst to provide data on the association
of both CHD and stroke risk with lower cotinine levels
(<0.7 ng/ml) resulting from lower nicotine exposure due to
public health measures. The low overall SHS exposure levels
(24% of non-smokers have cotinine levels between 0.06 and
0.70 ng/ml) mean our cohorts are well placed to provide infor-
mation about any continued cardiovascular risk in contempo-
rary groups with low SHS exposure. In line with a caseecontrol
study based on self-reported lifetime SHS exposure in the
context of falling SHS exposure levels,
27 our results provide little
support for an increased risk of CHD or stroke associated with
low levels of cotinine exposure. However, we are unable to
exclude adjusted HRs for CHD as high as 1.53, when comparing
cotinine levels between 0.06 and 0.70 ng/ml with cotinine
#0.05 ng/ml. We had limited information on the effects of
higher SHS exposure, associated with cotinine levels
0.71e15 ng/ml; only 13% of non-smokers had a cotinine level in
this range. Higher SHS exposure appeared to be associated with
a very modest increase in CHD risk and could only be impre-
cisely estimated. The results are, however, consistent with the
increase in CHD risk of 45% associated with such cotinine levels
in our earlier study, although we reported even greater elevations
in risk over shorter follow-up periods.
16
The pattern of overall association between cotinine level and
CHD risk among non-smokers in this study (expressed as a 2%
( 5% to 11%) increase in CHD risk for each doubling of cotinine
concentration) is weaker than in the previous study, where the
equivalent estimate was 16% (6% to 27%).
16 This study popu-
lation is appreciably older than in the previous study and
includes both genders. Although within this study neither
gender nor age appreciably inﬂuenced cotinineeCHD associa-
tions, the relative strengths of associations between many major
risk markers (especially active smoking) and CHD are recognised
to attenuate with increasing age,
28 29 so our estimates may be
lower than estimates which would be observed in a middle-aged
population. The point estimate of the effect of partner smoking
on CHD risk in never-smokers is considerably stronger than in
the published literature, while the association with stroke is
weaker.
1 Both estimates were post hoc and based on small
numbers and had wide conﬁdence limits.
The literature for stroke is less conclusive than for CHD and
fewer previous reports exist. Two caseecontrol studies
11 12 and
three prospective cohort studies
8e10 reported positive associa-
tions between self-reported SHS exposure and stroke risk,
although not all studies do. One prospective cohort had limited
power to detect an effect on cerebrovascular mortality as
distinct from cardiovascular mortality
15 and another had few
cases of stroke among non-smoking women.
14 Other studies did
not ﬁnd signiﬁcantly elevated risks of subarachnoid haemor-
rhage
30 or silent cerebral infarction
31 associated with SHS
exposure from living with a spouse who smokes. Our previous
prospective study showed no evidence of an association between
cotinine level in non-smokers and stroke risk. In this study, no
association was found between stroke and SHS exposure
measured by cotinine, over a very wide range of exposure
(cotinine from 0.05 to 15 ng/ml), or measured by living with
a spouse who smoked. However, our analyses have limited
precision and cannot exclude the possibility of a moderately
strong association. The lack of association with stroke is
consistent with our ﬁnding in this population of no association
of cotinine with variation in BP, an association that was
precisely estimated (table 1). By contrast, cotinine was associ-
ated with several CHD risk factors, including inﬂammatory
markers, despite not showing a strong association with CHD
events. We did not observe the expected associations between
active smoking and stroke, perhaps because we only studied
smokers of 1e9 cigarettes/day and not heavier smokers.
Strengths and weaknesses
A key strength of this study is the use of serum cotinine as an
objective measure of SHS exposure. Cotinine is the major
metabolite (70e80%) of nicotine, reﬂecting recent overall SHS
exposure, which enables more accurate estimates of the associ-
ations between SHS exposure and CVD than the use of self-
reported exposures, which may only partially capture exposures
from different sources.
32 33 Nicotine is metabolised into cotinine
by cytochrome P450. Although genetic factors controlling
nicotine metabolism may inﬂuence cotinine levels,
34 unless
these are systematically associated with CHD or stroke risk (for
which there is little current evidence), they should not bias the
estimation of cotinineeCHD associations.
While it is possible that other environmental inﬂuences on
cotinine levels exist, the evidence for them is weak at the present
time and we have included adjustment for BMI and alcohol
intake in our models, which did not have any important effect.
Cotinine is well validated as a biomarker of nicotine exposure
33
and also prevents appreciable misclassiﬁcation of active smokers
who fail to self-report smoking. We reclassiﬁed 76 participants
who reported being non-smokers but had cotinine levels >15 ng/ml
(a standard cut-off point) as active smokers. Including the 76
participants in the analysis in the highest exposure group did
not materially alter any of our results. This study was large,
combining cohorts of older men and women from socially and
geographically representative population studies. However, the
858 Heart 2010;96:854e859. doi:10.1136/hrt.2009.191148
Smoking and cardiovascular diseaseremoval of a substantial number of subjects with pre-existing
disease and low event rates limited the statistical power of the
study to detect small but important elevations in CVD risk. The
results are based entirely on older populations of retirement age,
exposed to contemporary SHS levels and at relatively high CVD
risk and may not be applicable to younger subjects or to popu-
lations with higher SHS exposure. In particular, this older
population is less likely to be exposed to SHS in the workplace
and may be less likely to be exposed in leisure public places than
younger populations.
CONCLUSIONS
The results suggest that the lower levels of cotinine prevailing in
the UK in 1998e2001, even before the introduction of legislation
to reduce SHS exposure in public places, were not apparently
associated with any marked increase in CHD or stroke risk in
older people. Our ﬁndings relating to low levels of SHS exposure
do not undermine previous epidemiological studies reporting
positive associations between SHS exposure and CHD or stroke
events, or the weight of laboratory studies suggesting causal
associations between SHS and elevated CHD risk. However,
because of the limited statistical power of our study and the
older age range of the population, further evidence from pooled
analyses of large population studies, including people of working
age, are needed to establish the associations between low-level
SHS exposure and CHD risk. In addition, studies speciﬁcally
examining the continuing impact of domestic partner smoking,
which is the main determinant of high SHS exposure in this
population,
18 would be valuable.
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